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INTRODUCTION
Platelets play important role in the initial wound healing; bleed-
ing from the wound leads to rapid activation of platelets
that release multiple growth factors and cytokines involved in
healing. Since the first demonstration of new bone formation
with a combination of autogenous bone graft and PRP, used
as a term by Marx,
1 those platelet-derived growth factors
have been thought to contribute to bone regeneration. However,
subsequent studies of its efficacy using different bone graft mate-
rials have led to conflicting results.
2-4 Results from studies
using non-cellular alloplastic graft materials were typically more
discouraging, even though there are some positive reports.
5-7
However, PRP’ s potential for delivering multiple factors is par-
ticularly appealing, as recent experiments have disclosed
that combinations of factors seem to work better than single
factors in bone regeneration.
8 The preparation and delivery of
platelet-derived growth factors (GFs) are likely to be critical,
but the biologic significance of different preparations of PRP
remain unclear, no standardized method has been devel-
oped, and there are only few studies that consider the factors
involved in platelet activation and conditions at the PRP
delivered site. 
Rapid vascularization of bone graft materials is a key step for
early and long-term successful osteogenesis, and the degree of
angiogenesis is related to the stimuli present in surrounding
tissues that allow preexisting vessels to start budding into the
freely applied grafts and the graft material itself.
9,10 Localized
angiogenic factor delivery has proven beneficial for bone
regeneration in numerous animal models by promoting neo-
vascularization, bone turnover, osteoblast migration and
mineralization.
11,12 Alloplastic bone substitutes have no cells in
the graft and need more time for vascularization or cell pop-
ulation and matrix production compare to autogenous cancellous
bone grafts. Considering that PRP can release factors involved
in angiogenesis and the short effective time of platelets and its
proteins, an angiogenic effect of PRP might be more important
to promote bone healing in alloplastic bone substitutes. This
approach is supposed to overcome the short term effect of the
PRP reported by previous study.
13
In the present study, the effects of increasing angiogenic fac-
tors in activated human PRP on the angiogenesis and subse-
quent osteogenesis were analyzed in vitro and in vivo. Four fac-
tors were considered to increase the angiogenic potential of the
PRP, including the concentrations of thrombin and calcium for
platelet activation, the subsequent release of vascular endothe-
lial growth factor (VEGF), production of platelet microparti-
cles (PMPs), and inclusion of only peripheral blood mononu-
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clear cells (PBMNCs) among white blood cells (WBCs). The first
three factors can vary in amount during the process of PRP
preparation and influence angiogenesis.
14-18 Also, PBMNCs
and platelets has been reported to be more potent in improv-
ing rat ischemic limb lesions, compared to platelets only or with
addition of polymorphonuclear leukocytes (PMNs).
19
We hypothesized that enhancement of the angiogenic poten-
tial of the human PRP could improve osteogenesis of acellu-
lar inorganic graft materials. To test this, β -tricalcium phosphate
(β -TCP) was placed, along with PRP, in a critical-size rat cal-
varial defect model. 
MATERIAL AND METHODS
1. Preparation of platelets for in vitro study
Commercially available human apheresed platelet plas-
mas were purchased from AllCells (Emeryville, CA, USA).
Donors were restricted to males under 30 years-old for qual-
ity control. All apheresed platelet plasmas were delivered
between 18-24 hours after withdrawal of blood, and the same
batch of platelets were used for each experiment. Total 6
samples from different donors were used for the study. To
exclude the effects of other factors in in vitro study, platelets
were isolated and suspended in HEPES-Tyrode’ s buffer
solution according to a previous report
20 at a concentration 1
× 10
9 /ml. Four different methods of platelet activation
described previously were used and modified.
1,3,4,21 Group A:
platelet-poor plasma and 10% CaCl2∙2H2O; Group B: platelet-
lysate with 0.1% Triton-X (Mallinckrodt, KY, USA); Group C:
142.8 U/ml of thrombin (Sigma, St. Louis, MO, USA) and 14.3
mg/ml CaCl2∙2H2O; Group D: 10 U/ml of thrombin and 2 mM
CaCl2∙2H2O after pre-activation with shear stress and 20 μ g/ml
collagen. For the application of shear stress, a tabletop vortex
machine was used. The rotation rate was 100 rpm for the
first 15 seconds and then increased to 3500 rpm for 5 minutes.
All samples were centrifuged for 10 minutes at 4000 g and acti-
vated PRP supernatants were harvested. All supernatants
were immediately stored at -80℃ until further analysis.
Because PBMNCs are mixture of heterogeneous cells and
mixture of adherent and nonadherent cells, they could not
involve in in vitro study.
2. Determination of GF concentrations and PMP formation
GF concentrations of bFGF, PDGF-BB, TGF-β , and VEGF in
the supernatants were determined using a Quantikine Assay
Kit according to the manufacturer’ s instructions (R&D
Systems, Minneapolis, MN, USA). Triplicate measurements were
performed for all assays (n = 3). The PMPs were collected and
the amount was checked depending on the preparation meth-
ods by Western blot as previously described.
21 Monoclonal anti-
body SZ22 (Beckman Coulter, Miami, FL, USA) against
platelet GPIIbα was used. 
3. Cell proliferation and vascular endothelial cell-assisted
osteogenesis assay 
Human cord blood-derived outgrowth endothelial like cells
(hCBOECs) and human bone marrow stromal cells (hBMSCs)
(Cambrex, Walkersville, MD, USA) were used. All cells were
seeded at a density of 2500 cells per well in 96-well culture plates
(BD, Franklin Lakes, NJ, USA) and incubated in the following
medium: 90 μ l IMDM supplemented with 1% FBS, 100 U/ml
of penicillin, and 100 μ g/ml of streptomycin and 10 μ l of
activated PRP supernatant from each condition (A-D) for 48
hours. The final cell numbers were assessed with MTS method
(CellTiter96, Promega, Madison, WI, USA) according to the man-
ufacturer’ s instruction.
For analysis of in vitro osteogenic differentiation assisted by
vascular endothelial cells, 1 × 10
4 /cm
2 hBMSCs were co-cul-
tured directly with 0.5 × 10
4 /cm
2 hCBOECs under EBM
medium supplemented with various activated platelet super-
natants (10% v/v), 1% FBS and 0.04% (v/v) hydrocortisone.
Activity of Alkaline phosphatase (ALP) at 5-th day after co-cul-
ture was evaluated with EnzoLyte FDP ALP Assay Kits
(AnaSpec, San Jose, CA, USA) and also, concentration of
secreted osteocalcin (OCN) at 10-th day was measured with Mid-
Tact Human OCN ELISA Kits (Biomedical Technologies,
Stoughton, MA, USA) as markers of early and late osteoblast
differentiation respectively. 
4. Animal Experiment
In this study, the PRP containing high amount of VEGF
and PMP and PBMNCs without PBPMNs was called angiogenic
factor-enriched PRP. PBMNCs and platelets were separately
isolated from the whole blood by density gradient centrifugation
(Histopaque-1077, Sigma, St. Louis, MO, USA) according to the
manufacturer’ s instruction. PBMNCs and PRP were collect-
ed by additional centrifugation (200 g and 1400 g, respectively)
and PRP was activated with the method described above.
In control groups using PRP, the group treated with platelet-
poor plasma and 10% CaCl2∙2H2O was excluded because no
significant difference was found between it and the group fol-
lowed Marx’ s protocol in in vitro study.
Harvard University and National Institute of Health (NIH)
animal care guidelines were followed in all procedures.
Twenty-eight NIH athymic rats, weighing approximately
200 g, were used and critical size (8 mm) cranial defects were
made. Anaesthesia and pain control followed recommended
routines for the species. The animals were anaesthetized
using isoflurane inhalation anaesthesia (E-Z Anesthesia,
Euthanex Corp., Palmer, PA, USA). Buprenorphine HCl, 0.02
- 0.03 mg/kg, was administered pre-surgically. In each animal,
one calvarial through-and-through osteotomy was trephined
into the central portion of the cranium using a dental handpiece
and trephine bur. 0.05 g of synthetic β -TCP (Synthograft
�, Bicon,
Boston, MA, USA) mixed with 50 μ l of the angiogenic factor-
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enriched PRP (activated PRP with the modified method + 2 ×
10
6 PBMNCs) was implanted into the defect. In control groups,
β -TCP or β -TCP with 50 μ l of conventional PRPs were grafted.
1) Analysis of blood vessel formation
After 2 weeks, periosteal blood flow over the cranial defect
was measured using a laser Doppler perfusion imaging
(LDPI) system (PeriScan, Perimed AB, Stockholm, Sweden). After
skin incision and meticulous supraperiosteal dissection under
inhalation anaesthesia, consecutive perfusion measurements
were obtained by scanning (the size of ROI; 10 × 10 mm
2) just
above the defects. Blood flow in the tail of the same animal was
used as internal control. After measuring periosteal blood
flow, animals were sacrificed with 100% carbon dioxide and
cervical dislocation. Cranial bones including the original
defect were harvested immediately after euthanization and
processed for immunohistochemistry. The tissue sections
were immunostained for von Willebrant factor (vWF) using a
commercial staining kit (Chemicon, Temecula, CA, USA)
and imaged by means of a Nikon Eclipse E800 light microscope
and a Spot RT digital camera (Diagnostic Instruments, Sterling
Heights, MI, USA). Blood vessels, indicated by vWF staining,
were counted manually at 100x magnification in randomly select-
ed areas of the defect, and normalized to tissue area with the
use of NIH Image J Software.
2) Analysis of New Bone Formation
At 8 weeks, the animals were euthanized, and the implants
were retrieved and fixed in 10% zinc-buffered formalin.
Following fixation, implants were scanned to measure bone min-
eral content (BMC, in grams) and bone mineral density (BMD,
in g/cm
2) in the region of interest (ROI) sized 8 × 8 mm
2 using
dual energy x-ray absorptiometry (DEXA, ODR2000+, Hologic
Inc., Waltham, MA, USA), three dimensionally with micro-com-
puted tomography (μ CT40, ScanoMedical, Bassersdorf,
Switzerland) and decalcified H&E staining.
5. Statistical analysis
Wilcoxon Rank Sum test was applied to evaluate the control
groups compared to experimental group. The level of signif-
icance was set at 5%.
RESULTS
1.VEGF release and PMP production
Activation with 0.1% Triton-X (Group B) evoked relatively
high release of all growth factors except for VEGF. Activation
with shear force, collagen, and low amount of calcium and
thrombin (Group D) showed a significant increase in the
release of VEGF (mean concentration 1264 pg/ml) as compared
to the other methods using high calcium and thrombin (mean
concentration 273 - 548 pg/ml), but the release of other growth
factors were lowered (Fig. 1A). All platelet agonists caused a
similar production of PMP except for Triton-X, what dis-
solved the platelet membrane (Fig. 1B). 
2. Effect of different PRPs on cellular behaviors
PRP supernatants from the modified method (Group D)
were significantly more mitogenic in both hCBOECs and
hBMSCs than all control groups (Group A to C, P < .05).
Because of cell toxicity of Triton-X, cell proliferation was sig-
nificantly inhibited by even small amounts of Triton-X (0.1%)
(Fig. 2A). In vascular endothelial cell-assisted osteogenic dif-
ferentiation of MSCs, ALP activity was not different between
the groups, except for the group treated with Triton-X. In con-
trast, the OCN concentration was significantly higher in the
group cultured with the modified PRP supernatant (Group D,
Fig. 2B, P < .05). 
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125 kDA
GP llbα
Standard     Group A      Group B     Group C     Group D 
Fig. 1. A: Release of growth factors measured with ELISA. Platelet-derived
growth factor (upper left), transforming growth factor-beta (upper
right), basic fibroblast-growth factor (lower left), vascular endothelial growth
factor (lower right). B: Production of platelet microparticles (PMPs)
detected with Western blot. Standard; molecular weight standard of GPIIb
α (125kD). Group A; activation with 10% CaCl 2 and platelet-poor plas-
ma (PPP), Group B; lysis with 0.1% Triton-X, Group C; activation with
142.8 U/mL thrombin and 4.3 mg/ml CaCl2, Group D; activation with
shear force, 20 mg collagen, 10 U/ml thrombin and 2 mM CaCl2. Values
represent mean and standard deviation.
A
B
Group A     Group B    Group C     Group D Group A     Group B    Group C     Group D
Group A     Group B    Group C     Group D Group A     Group B    Group C     Group D
P
D
G
F
 
(
n
g
/
m
L
)
0
 
 
 
 
 
 
 
 
 
 
2
0
 
 
 
 
 
 
 
 
4
0
 
 
 
 
 
 
 
6
0
 
 
 
 
 
 
 
 
8
0
 
 
 
 
 
 
 
 
1
0
0
T
G
F
-
b
e
t
a
 
(
n
g
/
m
L
)
0
 
 
 
 
 
 
 
 
2
0
 
 
 
 
 
 
4
0
 
 
 
 
 
 
6
0
 
 
 
 
 
 
8
0
 
 
 
 
 
1
0
0
 
 
 
 
1
2
0
F
G
F
-
b
a
s
i
c
 
(
p
g
/
m
L
)
0
 
 
 
 
 
 
5
0
 
 
 
1
0
0
 
 
 
1
5
0
 
 
 
2
0
0
 
 
 
2
5
0
 
 
 
 
3
0
0
 
 
 
3
5
0
V
E
G
F
 
(
p
g
/
m
L
)
0
 
 
 
 
2
0
0
 
 
4
0
0
 
 
 
6
0
0
 
 
8
0
0
 
 
1
0
0
0
 
 
 
2
0
0
 
 
 
1
4
0
010 J Adv Prosthodont 2010;2:7-13
3. In vivo animal experiments
1) Angiogenesis and Perfusion
β -TCP without or with various types of human PRPs were
implanted into the cranial defects of athymic rats to determine
the effects of human PRP treatment on wound angiogenesis
(Fig. 3). A significant increase of blood perfusion was observed
in the defects treated with angiogenic factors-enriched PRP at
2 weeks, compared to other conditions (31 - 42% improvement,
P < .05). The blood vessel densities within the defects compared
to the β -TCP only grafts (Group A, 48 ± 18 vessels/cm
2),
showed significantly higher neovascularization in the exper-
imental group (Group D, 98 ± 20 vessel/cm
2; P < .05) (Fig. 4A-
C).
2) New bone formation
Analysis of cranial implants indicated that all groups showed
favorable tissue response without significant inflammatory reac-
tion (Fig. 5). Human angiogenic factors-enriched PRP (Group
D) led to significantly increased BMC and BMD versus control
defects grafted with β -TCP only (Group A, P < .05) (Fig. 6).
Although some control groups with PRPs (Group B and C)
showed higher BMC and BMD values compared to the group
grafted with β -TCP only (Group A), they were not statistically
significant. These findings were confirmed by 3D μ CT imag-
ing, which revealed the formation of a continuous bone mass
across the defects (Fig. 7). The control condition without any
PRPs demonstrated significantly decreased bone formation.
DISCUSSION
Primary hypothesis of this study was the rapid establishment
of vascular network. It may play the key role for repro-
ducibility of PRP effect in bone regeneration. Our previous study
showed increased initial angiogenesis by animal PRP enhanced
bony regeneration in the critical size defect without any graft
material.
22 In this study authors checked whether human
PRP showed the same effect around acellular synthetic graft
material before clinical trial. Also our hypothesis can be sup-
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Fig. 3. A-C: Laser Doppler perfusion images of periosteal region of
the cranial defect at 2 weeks after graft procedures. A. β -TCP only, B. β -
TCP and conventional PRP activated with 142.8 U/ml thrombin and 4.3
mg/ml CaCl2, C. β -TCP and angiogenic factor-enriched PRP (PRP acti-
vated with shear force, 20 mg/ml collagen, 10 U/ml thrombin and 2 mM
CaCl2, and containing peripheral blood mononuclear cells), D. Mean per-
fusion of each group (P < .05). The mean blood flows are normalized to
the perfusion measured in the tail of the same animal (unit: voltage). White
dotted circles manifest the original defects. Increased blood flow was indi-
cated as color change from dark red to navy blue.
Fig. 2. A: Proliferation of cord blood-derived outgrowth endothelial-like
cells (left) and human bone marrow stromal cells (hBMSCs) (right) as indi-
cated by absorbance of formazan at 490 nm after 48 hrs. B: Osteogenic dif-
ferentiation of hBMSCs modulated by human cord blood-derived out-
growth endothelial-like cells (hCBOECs). Activity of alkaline phos-
phatase (left, unit: intensity of fluorescence). Production of osteocalcin
(right, ng/mL). hBMSCs (1 ×10
4/cm
2) and hCBOECs (1 ×10
4/cm
2) were
co-cultured with IMDM media, 1% FBS, 10
-7 M dexamethasone and each
PRP (100 μ l/ml). Group A; activation with 10% CaCl2 and platelet-
poor plasma (PPP), Group B; lysis with 0.1% Triton-X, Group C; activation
with 142.8 U/ml thrombin and 4.3 mg/ml CaCl2, Group D; activation with
shear force, 20 mg/ml collagen, 10 U/ml thrombin and 2 mM CaCl2. Values
represent mean and standard deviation.
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ported by other recent study.
23 Although VEGF is potent
angiogenic factor and positive correlation was observed
between VEGF levels and bone formation, its absolute amounts
in platelet is very low, therefore it may have minimal effect on
osteogenesis. For increasing the angiogenic potential, other fac-
tors should be considered. In the present study, three methods
such as a control of the concentration of thrombin, increasing
PMP production and including only PBMNCs among white
blood cell components, were used for that purpose. 
Although calcium and thrombin induce immediate growth
factor release from platelet in a dose-dependent manner,
24
high concentrations of thrombin could present an adverse effect
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Fig. 4. Staining for vWF in critical size (8 mm) rat craniotomy defects fol-
lowing implantation of β -TCP only (A) and β -TCP + angiogenic factors-
enriched PRP (A-PRP, B) at 2 weeks. Blood vessels are identified as cir-
cular structure with dark brown color: Quantitative analysis of the
number of blood vessels in both groups (C). Values represent the mean
and standard deviation.
Fig. 5. Photomicrographs of histological sections from critical size 8 mm
rat craniotomy defects following implantation of β -TCP (Synthograft
�)
and several types of PRP at 7 weeks. A: β -TCP only, B: β -TCP and
0.1% triton-X treated PRP, C: β -TCP and PRP activated with 142.8
U/ml thrombin and 4.3 mg/ml CaCl2, D: β -TCP and angiogenic factors-
enriched PRP (activated with shear force, 20 mg/ml collagen, 10 U/ml
thrombin and 2 mM CaCl2and containing peripheral blood mononuclear
cells).
Fig. 6. Bone mineral density (A) and bone mineral content (B) of critical
size (8 mm) rat craniotomy defects following implantation of β -TCP
(Synthograft
�) and several types of human PRP in athymic rats at 7 weeks.
Group A. β -TCP only, Group B. β -TCP and 0.1% triton-X treated PRP,
Group C. β -TCP and PRP activated with 142.8 U/ml thrombin and 4.3
mg/ml CaCl2, Group D. β -TCP and angiogenic factors-enriched PRP (acti-
vated with shear deformation, 20 mg/ml collagen, 10 U/ml thrombin
and 2 mM CaCl2and containing peripheral blood mononuclear cells). Values
represent mean and standard deviation.
Fig. 7. MicroCT image reconstruction of critical size (8 mm) rat craniotomy
defects at 7 weeks. A: β -TCP only, B: β -TCP and human angiogenic fac-
tors-enriched PRP in athymic rat. It shows positive effect of PRP in our
experimental group.
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on migration and proliferation of vascular endothelial cells.
14,15
Also thrombin has a threshold effect in relation to VEGF
release, and high concentrations of thrombin decrease the
release of VEGF.
25 Because the exact threshold mechanism and
concentration of thrombin are unknown, we set the concentration
of thrombin and calcium optimal for vascular endothelial
cell proliferation. In the present study, incorporation of other
platelet activators, along with collagen and mechanical stim-
ulus (shear force), increased the initial secretion of VEGF as com-
pared to activation of 10 U/1 × 10
9 platelets with thrombin
under 2 mM CaCl2 only (Data are not shown). Collagen and
shear stimuli were intended to compensate for the decrease of
other growth factors and increase the production of PMPs, but
they also further increased the VEGF secretion. This may be
explained by a significant release of VEGF from platelets
under a combination of low concentration of each agonist that
causes platelet aggregation induced by shear stress.
20
Combination of these three platelet activators results in significant
VEGF release (2.3 - 4.6 times), compared to other activation meth-
ods described previously. 
It is interesting that Triton X, a solubilizer of platelet mem-
brane did not increase the release of VEGF as compared to oth-
er platelet growth factors. The result implicates that VEGF might
have a different releasing mechanism and some interactions
with Triton-X.
Significant positive correlation was observed between angio-
genic factor level and cell behaviors. Proliferation of both
hCBOECs and hBMSCs were influenced by the preparation
method of platelets (Fig. 2A). Although it is not clear whether
the concentration of thrombin and calcium or the composition
of release molecules is responsible for this effect, the mitogenic
activity of platelet supernatant generated by the modified
method (Group D) was higher than that of platelets activated
with high thrombin and calcium. The relatively high proliferation
in platelets activated with 10% calcium was likely due to
additional release of bFGF and it might partially compensate
for the inhibition by the high concentration of calcium. Triton-
X, even in a low concentration, showed an inhibitory effect on
cell proliferation. Osteogenic differentiation of hBMSCs sup-
ported by hCBOECs also was influenced by different levels of
angiogenic factors (Fig. 2B). Activated platelet supernatants were
previously reported to hold a potent mitogenic and chemotactic
activity for mesenchymal progenitor cells, however, to decrease
osteogenic differentiation.
26 ECs, in contrast, enhance the
osteogenic potential of bone marrow stromal cells (BMSCs)
grown in co-culture in vitro, likely via BMP-2 production.
27 In
this study, increased angiogenecity of the PRP significantly
enhanced the late stage osteogenic differentiation of hBMSCs
co-cultured with hCBOECs. Although it has been reported that
thrombin increases proliferation and migration of bone mar-
row stromal cells.
15 These effects was found only up to 1
U/ml thrombin. This report may explain why the proliferation
rate and osteogenic differentiation of hBMSCs in the PRP
with a high concentration of thrombin is low.
The in vivo findings reflected the in vitro results. For maximizing
angiogenic potential of the PRP, only PBMNCs were includ-
ed among white blood cells, usually contained during the PRP
preparation. The experimental group grafted with β -TCP
and angiogenic factor-enriched PRP showed a 59% higher
periosteal perfusion than those grafted with β -TCP only (Fig.
3). Considering the importance of the periosteal blood supply
in fracture healing,
28 the periosteal perfusion above a defect might
reflect overall re-vascularization of the defects after surgery.
Vessel densities in the defects were in accordance with the LDPI
findings (Fig. 4). PBMNCs are known to include the source of
cells of monocyte lineage secreting angiogenic factors, but PMNs
likely show antiangiogenic effect due to the release of neutrophile
elastase.
29,30 Therefore, the additive effects of PBMNCs and mod-
ified PRP could explain the enhanced early angiogensis and
subsequent osteogenesis in this study. 
Bone density was improved to average of 71% by angiogenic
factor-enriched PRP, compared to the control group grafted with
only β -TCP (Fig. 6). This finding suggests that the enhanced
angiogenic activity contributed to later osteogenesis. However,
long-term animal experiments are needed to confirm these find-
ings. 
CONCLUSION
These results confirm that enhancing the angiogenic poten-
tial of PRP can be advantageous when grafted with non-cel-
lular alloplastic graft material. This combination resulted in faster
and more extensive new bone formation, likely due to
enhanced angiogenesis. However, the release mechanisms
of platelet-derived growth factors are complicated, and many
factors should be considered and harmonized to maximize the
functions of those growth factors. Although, additional stud-
ies should be performed to confirm the findings of this report,
these findings provide optimistic prospects for bone graft
procedures.
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